🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

My unfortunate combination of socks paired with the Hospital’s new scrubs colour scheme reminds me of The Joker...I’m just off to find some steps to dance down..

I never thought I would look forward so much to pain, itching, fever, headache, joint pain and tenderness...but it looks like they did it..Well done Oxford! #oxfordvaccine #lancet #NIHR

The NNT.com is my new favourite website for Nihilistic Evidence based medicine geeks. It gives the NNT for common interventions with surprising results...making you realise just how bad our 'gold standard' therapies in medicine are thennt.com

Was about to give a talk on new therapies for kidney disease when I realised the spellcheck had missed a crucial letter ‘f’ in my concluding slide...”SGLT2 inhibitors have led to a paradigm shit in guidelines” was not quite what I had intended to say...

My mum on the TV today talking about John Hume and his amazing wife Pat who made it all possible...

If you ever needed confirmation that cardiologists have a God complex...#ESC2020

Dapa CKD results: works just as well for people with diabetes as non-diabetics. NNT=19 for primary endpoint. SGLT2i are total game changers for people with CKD.

here's hoping...

This just in from Brian Fantana’s preprint on the latest covid vaccine results.... youtu.be/pjvQFtlNQ-M via YouTube

2020 was really shitty. Looking forward to the hole of 2021

💥Just out! Persistence of antibody response to SARS-CoV-2 in a cohort of hemodialysis patients with COVID-19 📖Read full paper in NDT, open access: 👉bit.ly/30Hhozm🔓 Suzanne Forbes #hemodialysis #COVID19 #SARSCoV2 #vaccination #immunity #antibodies

Finerenone meets primary endpoint in Phase III FIGARO- DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes. More great news for our DKD patients.

St George Street Capital are delighted to announce the publication of our protocol paper in the peer-reviewed journal BMJ Open, which discusses our approach to the ARCADIA clinical trial in COVID19. bmjopen.bmj.com/content/11/12/…

ORIGINAL RESEARCH: Efficacy of Difelikefalin for the Treatment of Moderate-to-Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies Joel M. Topf, MD FACP kieran mccafferty buff.ly/3a9HPpS